Cargando…
Immunological responses following the third dose of the BNT162b2 SARS-CoV-2 vaccine among Japanese healthcare workers
INTRODUCTION: A limited number of studies have shown a decline in antibody titers in healthcare workers beyond six months after the second dose of the BNT162b2 vaccine, and has been insufficiently investigated yet in the respective Asian ethnic groups. METHODS: We conducted a longitudinal observatio...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9339081/ https://www.ncbi.nlm.nih.gov/pubmed/35921965 http://dx.doi.org/10.1016/j.jiac.2022.07.006 |
_version_ | 1784760100140875776 |
---|---|
author | Tamura, Miku Fujita, Retsu Sato, Tomoaki Sato, Ryohei Kato, Yasuyuki Nagasawa, Mitsuaki Matsumoto, Tetsuya |
author_facet | Tamura, Miku Fujita, Retsu Sato, Tomoaki Sato, Ryohei Kato, Yasuyuki Nagasawa, Mitsuaki Matsumoto, Tetsuya |
author_sort | Tamura, Miku |
collection | PubMed |
description | INTRODUCTION: A limited number of studies have shown a decline in antibody titers in healthcare workers beyond six months after the second dose of the BNT162b2 vaccine, and has been insufficiently investigated yet in the respective Asian ethnic groups. METHODS: We conducted a longitudinal observational study on 187 healthcare workers and other personnel and healthy adults at least eight months after vaccination at the International University of Health and Welfare. RESULTS: The baseline (before the third dose of BNT162b2) anti-receptor binding domain (RBD) IgG level was 569[377–943] AU/mL 245[240–250] days after the second dose. The mean antibody titer of participants aged 20–29 years was 4.6 times higher than that of participants aged 70–79 years. After booster vaccination, serum anti-RBD antibody levels were elevated in all participants with a median titer of 23,250[14,612–33,401] AU/mL 21[19–23] days after the third dose. The median post-booster antibody titers in the 20–29, 30–39, 40–49, 50–59, 60–69, and 70–79 years age groups were 30.6, 33.0, 33.8, 27.4, 50.1, and 90.3 times, respectively, higher than the pre-booster ones. Antibody levels were 15% lower in daily drinkers compared to nondrinkers, suggesting that daily alcohol consumption can prevent antibody levels from increasing after vaccination. Our results show decreased antibody titers after two doses of the vaccine, especially in the elderly; however, the third dose of the vaccine resulted in a significant increase in antibody titers in all age groups. CONCLUSIONS: We provided information on antibody responses following primary and booster doses of the BNT162b2 mRNA COVID-19 vaccine in Japan. |
format | Online Article Text |
id | pubmed-9339081 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93390812022-08-01 Immunological responses following the third dose of the BNT162b2 SARS-CoV-2 vaccine among Japanese healthcare workers Tamura, Miku Fujita, Retsu Sato, Tomoaki Sato, Ryohei Kato, Yasuyuki Nagasawa, Mitsuaki Matsumoto, Tetsuya J Infect Chemother Original Article INTRODUCTION: A limited number of studies have shown a decline in antibody titers in healthcare workers beyond six months after the second dose of the BNT162b2 vaccine, and has been insufficiently investigated yet in the respective Asian ethnic groups. METHODS: We conducted a longitudinal observational study on 187 healthcare workers and other personnel and healthy adults at least eight months after vaccination at the International University of Health and Welfare. RESULTS: The baseline (before the third dose of BNT162b2) anti-receptor binding domain (RBD) IgG level was 569[377–943] AU/mL 245[240–250] days after the second dose. The mean antibody titer of participants aged 20–29 years was 4.6 times higher than that of participants aged 70–79 years. After booster vaccination, serum anti-RBD antibody levels were elevated in all participants with a median titer of 23,250[14,612–33,401] AU/mL 21[19–23] days after the third dose. The median post-booster antibody titers in the 20–29, 30–39, 40–49, 50–59, 60–69, and 70–79 years age groups were 30.6, 33.0, 33.8, 27.4, 50.1, and 90.3 times, respectively, higher than the pre-booster ones. Antibody levels were 15% lower in daily drinkers compared to nondrinkers, suggesting that daily alcohol consumption can prevent antibody levels from increasing after vaccination. Our results show decreased antibody titers after two doses of the vaccine, especially in the elderly; however, the third dose of the vaccine resulted in a significant increase in antibody titers in all age groups. CONCLUSIONS: We provided information on antibody responses following primary and booster doses of the BNT162b2 mRNA COVID-19 vaccine in Japan. Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2022-11 2022-07-31 /pmc/articles/PMC9339081/ /pubmed/35921965 http://dx.doi.org/10.1016/j.jiac.2022.07.006 Text en © 2022 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Article Tamura, Miku Fujita, Retsu Sato, Tomoaki Sato, Ryohei Kato, Yasuyuki Nagasawa, Mitsuaki Matsumoto, Tetsuya Immunological responses following the third dose of the BNT162b2 SARS-CoV-2 vaccine among Japanese healthcare workers |
title | Immunological responses following the third dose of the BNT162b2 SARS-CoV-2 vaccine among Japanese healthcare workers |
title_full | Immunological responses following the third dose of the BNT162b2 SARS-CoV-2 vaccine among Japanese healthcare workers |
title_fullStr | Immunological responses following the third dose of the BNT162b2 SARS-CoV-2 vaccine among Japanese healthcare workers |
title_full_unstemmed | Immunological responses following the third dose of the BNT162b2 SARS-CoV-2 vaccine among Japanese healthcare workers |
title_short | Immunological responses following the third dose of the BNT162b2 SARS-CoV-2 vaccine among Japanese healthcare workers |
title_sort | immunological responses following the third dose of the bnt162b2 sars-cov-2 vaccine among japanese healthcare workers |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9339081/ https://www.ncbi.nlm.nih.gov/pubmed/35921965 http://dx.doi.org/10.1016/j.jiac.2022.07.006 |
work_keys_str_mv | AT tamuramiku immunologicalresponsesfollowingthethirddoseofthebnt162b2sarscov2vaccineamongjapanesehealthcareworkers AT fujitaretsu immunologicalresponsesfollowingthethirddoseofthebnt162b2sarscov2vaccineamongjapanesehealthcareworkers AT satotomoaki immunologicalresponsesfollowingthethirddoseofthebnt162b2sarscov2vaccineamongjapanesehealthcareworkers AT satoryohei immunologicalresponsesfollowingthethirddoseofthebnt162b2sarscov2vaccineamongjapanesehealthcareworkers AT katoyasuyuki immunologicalresponsesfollowingthethirddoseofthebnt162b2sarscov2vaccineamongjapanesehealthcareworkers AT nagasawamitsuaki immunologicalresponsesfollowingthethirddoseofthebnt162b2sarscov2vaccineamongjapanesehealthcareworkers AT matsumototetsuya immunologicalresponsesfollowingthethirddoseofthebnt162b2sarscov2vaccineamongjapanesehealthcareworkers |